Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.98, $0.23 better than the analyst estimate of $2.75. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.04 billion.

GUIDANCE:

Charles River Laboratories sees FY2023 EPS of $9.70-$10.90. Charles River Laboratories sees FY2023 revenue of $11.37 billion. Revenue growth, reported up 1.5-4.5%. Sees Revenue growth, organic up 4.5-7.5%.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.